

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Corporate Office: 201, 2nd Floor, A wing, Corporate Avenue, Sonawale Lane,
Goregaon East, Mumbai, Maharashtra 400063

Reg.off. - C- 273, C block, sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh,
India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

To,

BSE Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Scrip code: 531207

Subject: Outcome of Board Meeting

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., 04th February, 2026, has inter alia considered and approved the following matters:

1. Un-Audited Financial Results of the Company for the third quarter ended 31st December, 2025, together with all the Limited Review report for the Third quarter ended 31st December, 2025 prepared in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is attached herewith.

The un-audited financial results for the first quarter ended along with Limited Review Report will be made available on the Company's website.

The meeting commenced at 02:00 p.m. and concluded at 03:15 p.m.

Kindly take the same on record.

FOR CRESANTO GLOBAL LIMITED

(Nishant Bajaj)

Director

DIN: 06634036

Date: 04th February, 2026

Place: Mumbai

Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Cresanto Global Limited

1. We have reviewed the accompanying statement of unaudited standalone Financial Results of **Cresanto Global Limited (Formerly known as Raymed Labs Limited)** ("the Company") for the quarter ended 31st December 2025 ("the statement"). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations)
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **K T P S & Co.**
Chartered Accountants
Firm's Registration No. 134942W



CA **Anurag Khandelvia**
Partner

Mem. No. 172909
UDIN: 26172909HTRJUI4387


Place: Mumbai
Date: 04/02/2026

CRESANTO GLOBAL LIMITED (formerly known as Raymed Labs Limited)
STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE PERIOD ENDED DECEMBER 31, 2025

(INR in Lakhs)							
Particulars	Note No.	For The qtr ended December 31, 2025	For The qtr ended September 30, 2025	For The qtr ended December 31, 2024	For the nine month ended December 31, 2025	For the nine month ended December 31, 2024	For the Year ended March 31, 2025
I Revenue							
Revenue from Operations	22	-	5.39	-	5.39	-	-
Other Income	23	2.00	-	0.86	2.00	0.86	52.59
Total Income		2.00	5.39	0.86	7.39	0.86	52.59
II Expenses							
Purchases of Stock in Trade		-	5.22	-	5.22	-	-
Change in Inventories of Finished Goods/Work-in-progress/ Stock in T	24	-	-	-	-	-	-
Employee Benefits Expenses	25	6.40	0.60	0.40	10.60	2.10	21.45
Finance Costs	26	-	-	0.00	0.01	0.00	11.49
Depreciation and Amortization Expenses	27	-	-	0.15	-	0.44	0.44
Other Expenses	28	5.04	0.42	25.22	11.05	26.65	37.26
Total Expenses		11.44	6.24	25.77	26.88	29.20	70.64
III Profit before tax (I- II)		(9.44)	(0.85)	(24.91)	(19.49)	(28.33)	(18.05)
IV Less: Tax Expense:							
Current Tax		-	-	-	-	-	-
MAT Credit Entitlement		-	-	-	-	-	-
Deferred Tax		-	-	-	-	-	-
Total Tax Expense		-	-	-	-	-	-
V Profit for the Year (III-IV)		(9.44)	(0.85)	(24.91)	(19.49)	(28.33)	(18.05)
VI Other Comprehensive Income							
Items that will not be reclassified to profit or loss							
Re-measurement gains/ (losses) on defined benefit obligations		-	-	-	-	-	-
Tax Effect on above		-	-	-	-	-	-
Other Comprehensive Income for the year, net of tax		-	-	-	-	-	-
VII Total Comprehensive Income for the year (V+VI) (Comprising Profit and Other Comprehensive Income for the year)		(9.44)	(0.85)	(24.91)	(19.49)	(28.33)	(18.05)
VIII Earnings Per Equity Share (Face Value INR 10 Per Share):	29						
Basic and Diluted (INR)		(0.22)	(0.02)	(0.58)	(0.46)	(0.66)	(0.42)
Summary of Significant Accounting Policies	2-4						

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors



Prashant Nathmal Bajaj
Managing Director & CFO
DIN- 06634046
Place: Mumbai
Dated: 04.02.2026